Viz.ai presented new data supporting the use of its technology to coordinate care for acute ischaemic stroke, haemorrhagic stroke, and clinical trial recruitment at the International Stroke Conference (ISC) 2021 (17–19 March, virtual), according to a company press release.
Ameer E Hassan of the Valley Baptist Medical Center, Harlingen, USA, presented two studies utilising Viz LVO to improve care coordination for ischaemic stroke patients requiring treatment across health systems and at a standalone centre. Viz.ai reports that the data demonstrated reduced door-in door-out times at primary stroke centres (PSCs), improved door-in-to-puncture times at comprehensive stroke centres (CSCs), and improved reperfusion rates.
Brian Jankowitz of Cooper University Health Care, Camden, USA, shared how Viz.ai’s clinical trial enrolment software, Viz RECRUIT, has led to faster patient detection and increased enrolment velocity in the AI ENRICH trial.
The first study presented by Hassan, ‘The implementation of artificial intelligence significantly reduces door-in door-out times in primary care center prior to transfer,’ compared the time interval between entering and leaving one of Valley Baptist’s 12 PSCs before being transferred to the CSC for an emergent operation. The study showed a significant 45%, or 102.3-minute, average reduction in door-in door-out time for patients whose care was coordinated through the Viz application. In addition, there was an 11.4% improvement in modified Rankin Scale (mRS) scores, which measure stroke outcomes.
The second study presented by Hassan, ‘Implementation of artificial intelligence stroke software significantly improves door-in to puncture time interval and reperfusion rates,’ evaluated the impact of Viz LVO on the time interval at the CSC between door-in to puncture time for non-transfer patients. Patients treated using Viz LVO showed significant improvements, this time in terms of treatment time and revascularisation. The software shaved an average of 86.7 minutes from each procedure and delivered a 10.8% improvement in the rate of good revascularisation.
“Our two studies show that the incorporation of Viz LVO to coordinate care for ischaemic stroke patients is associated with significant time savings across a hub and spoke model and also at comprehensive stroke centres,” said Hassan. “Because we know that ‘time is brain,’ these improvements in the PSC and CSC settings could lead to significant advances in functional outcomes, reduced mortality and shorter hospital stays.”
Brian Jankowitz presented results from ‘Large scale, CT evaluation can improve screening for multicenter stroke trials.” The data demonstrated that artificial intelligence can automate the detection and triage of ICH patients and subsequently increase enrolment velocity in clinical trials. AI ENRICH is a prospective trial that utilises Viz RECRUIT to identify potentially eligible study subjects. The utilisation of Viz.ai’s technology was associated with a 41% increase in screening rate and a 213% increase in enrolment rates.
“Viz ICH and Viz RECRUIT have increased enrolment in the AI ENRICH trial,” said Jankowitz. “Increasing enrolment velocity will enable a faster completion of the trial and ultimately help improve our understanding of this devastating condition.”
“We are so grateful to Hassan and Jankowitz and their teams, and to all the healthcare providers around the world who have dedicated their careers to improving the lives of stroke patients,” said Chris Mansi, co-founder and CEO of Viz.ai. “At, that mission is at the core of our work. We want to improve how healthcare is delivered, reducing time to treatment and improving access to care. The magnitude of time saved in studies conducted by Hassan and his team demonstrates how intelligent software can be harnessed to significantly reduce disability from stroke.”